X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...
The Manila Times18h
Nxera Pharma's Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder
Tempero Bio was created in 2020 by the venture firm Aditum Bio to advance the clinical development of a portfolio of potent, ...
Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC) and Lexeo Therapeutics, Inc. (LXEO)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Century Therapeutics (IPSC – Research Report) ...
pharmaphorum19h
Pharma’s climate change vulnerability and opportunity
With this level of insight, pharma companies can quantify and understand the risks to their assets and supply networks across various timeframes, risk categories, and climate scenarios – and ...
money.rediff21h
GlaxoSmithKline Pharmaceuticals Ltd.
Mar 19, 2025 22:44 SBFC Finance Promoter Sells 1.3% Stake for Rs 112 Crore SBFC Holdings Pte, a promoter of SBFC Finance, divested a 1.3% stake in the company for Rs 112 crore through an open market ...